MSI
57
5
THC
71
4
DOV
80
-2
KO
60
3
TSCO
57
-8
ETR
57
2
HIG
70
3
UAL
56
-8
LLY
56
3
VZ
29
2
NWL
37
6
PCG
85
4
HRB
68
5
IR
82
2
PEG
53
5
SYK
60
5
PG
60
4
DG
24
-4
XRX
48
2
WYNN
44
7
MSI
57
5
THC
71
4
DOV
80
-2
KO
60
3
TSCO
57
-8
ETR
57
2
HIG
70
3
UAL
56
-8
LLY
56
3
VZ
29
2
NWL
37
6
PCG
85
4
HRB
68
5
IR
82
2
PEG
53
5
SYK
60
5
PG
60
4
DG
24
-4
XRX
48
2
WYNN
44
7
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
30

APLS
Apellis Pharmaceuticals

Last Price:
44.18
Seasonality Move:
-1.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.59M
Cash Flow: $-97.97M
Price / Cash Flow: 0
Annual Sales: $1.63
Price / Book: 29.66

Profitability

EPS (TTM): -4.48000
Net Income (TTM): $-528.63M
Gross Margin: $338.08M
Return on Equity: -195.18%
Return on Assets: -62.02%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 0.48
Current Ratio: 3.1
Quick Ratio: 2.33

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 39.21

APLS Technical Analysis vs Fundamental Analysis

Sell
30
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?